{"id":"W3158136113","doi":"10.1038/s41375-021-01257-7","title":"Hairy cell leukemia and COVID-19 adaptation of treatment guidelines","year":2021,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Cilag; Canadian Institutes of Health Research; Kite Pharma; Genentech; Ascentage Pharma; Pharmacyclics; Agios Pharmaceuticals; Astellas Pharma; Adaptive Biotechnologies; Astex Pharmaceuticals; H. Lundbeck A/S; TG Therapeutics; Royal Marsden NHS Foundation Trust; CancerCare Manitoba Foundation; MEI Pharma; MacroGenics; Sunesis; University of Pittsburgh; AbbVie; National Cancer Institute; Servier; Gilead Sciences; Teva Pharmaceutical Industries; Celgene; Novartis; Pfizer; Biogen; AstraZeneca; Amgen; National Institutes of Health; Leukemia and Lymphoma Society of Canada; BeiGene; Hairy Cell Leukemia Research Foundation; GlaxoSmithKline","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; Medicine; Hairy cell leukemia; Immunosuppression; Intensive care medicine; Life expectancy; Leukemia; 2019-20 coronavirus outbreak; Immunology; Disease; Virology; Internal medicine; Infectious disease (medical specialty)","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005111861,0.0007449469,0.003298073,0.000424164,0.0001045658,0.00004350248,0.0002514061,0.0007787566,0.0002913652],"category_scores_gemma":[0.001109483,0.0005678361,0.000770971,0.0006504678,0.0002689468,0.00007206118,0.0002296286,0.0004596593,0.00007840685],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1480937,"about_ca_system_score_gemma":0.2001287,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007350176,"about_ca_topic_score_gemma":0.0002108506,"domain_scores_codex":[0.9959179,0.000276436,0.001545822,0.0009898868,0.0006929721,0.0005769464],"domain_scores_gemma":[0.9962473,0.0008331747,0.0005989978,0.001189342,0.0003870036,0.0007441696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005524958,0.00006117296,0.000004020852,0.05389557,0.000481857,0.0008184744,0.000363555,0.0002786096,0.000005189457,0.0001068243,0.01134959,0.9325799],"study_design_scores_gemma":[0.008387472,0.0004653251,4.694156e-7,0.008899462,0.002183446,0.00126082,0.000241696,0.006337736,0.00003387121,0.00001243635,0.9717754,0.0004018358],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001483393,0.9951183,0.0004645997,0.00007076382,0.0001746347,0.00159303,0.0001036775,0.00008959858,0.002237057],"genre_scores_gemma":[0.00003331714,0.9837425,0.00329405,0.0002624893,0.0005062148,0.0002312764,0.0008986363,0.000136507,0.01089501],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9604259,"threshold_uncertainty_score":0.9996773,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1891866795627362,"score_gpt":0.4336963452685132,"score_spread":0.244509665705777,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}